|
Post by orlon on Jul 6, 2015 14:20:10 GMT -5
I'm afraid I'm still confused about lending stock thing so it can be shorted. One loans out their MNKD stock to short sellers, gets a dividend check, buys more MNKD stock and lends that out to short sellers, gets a dividend check to buy more MNKD stock etc etc. I see folks on this board reaping benefits from the transaction...don't get me wrong I'm a capitalist like everyone else, but if hedge funds and institutional holders are doing the same thing, how can I expect the share price to increase, the company to move forward with any confidence, and the company to be successful? I've heard the arguments about short squeeze, expectations of grand news, and how the stock price will soar when the scripts improve...none in my opinion meet muster. In my opinion MNKD is now in a endless cycle of dividend/shorting. Just my opinion.
|
|
|
Post by orlon on Jul 2, 2015 9:49:30 GMT -5
Anyone know who/what/why the PPS is being hammered again today? This seems to be an ongoing thing. Several folks at the YMB are pointing their fingers at Sanofi and I have admit I'm intrigued by some of their arguments. I personally never thought much of a 'slow roll out.' If you have a blockbuster drug that would help millions and make millions why not get out in front of it? An ad of some vagrant 'breathing easy' could as well have been an ad for how to get Uncle Bill off the crack (photo-shop the dreamboat for a crack pipe.) It's almost 8:00 am...I'm going to get hammered!
|
|
|
Post by orlon on Jul 1, 2015 14:01:25 GMT -5
Great stuff...and yet the stock price continues to drop. I simply don't understand this!
|
|
|
Post by orlon on Jun 25, 2015 9:59:58 GMT -5
Did anyone send a tweet to the station to correct the information? Or did we all just sit on our hands and do nothing?
|
|
|
Post by orlon on Jun 23, 2015 13:29:44 GMT -5
I do not view this as a 'woe is me' document as others seem to do. First of all it is a draft, not a final version; second, it reflects the label affixed by the FDA. The objectionable part is at the end of the document that requires one of two exceptions, injection site problems and/or workplace prohibitions. Overall this should be viewed that at least the VA is looking at AFREZZA, and second it is still a doctor/patient decision. Of note is the fact that TRICARE users...DoD, have access to AFREZZA at EXPRESS SCRIPTS...both active duty and military retirees. As a military retiree, I can use the VA pharmacy or not...I can also use TRICARE if need be through Express Scripts.
|
|
|
Post by orlon on Jun 17, 2015 14:55:31 GMT -5
Apologize for being redundant. This was news to me...don't look at sub boards.
|
|
|
Post by orlon on Jun 17, 2015 14:20:06 GMT -5
There is an excellent article regarding AFREZZA in Canada.com. Click on HEALTH the scroll down on left hand side. Speaks loudly on needle use and frustrations of injection. Makes me wonder why clowns like Looking for Diogenes and othe Seeking Alpha twits don't wake up and smell the coffee.
|
|
|
Post by orlon on Jun 11, 2015 22:04:02 GMT -5
Trend, I agree completely. The fact that short sales are driving the stock price down when in fact many contribute to the stock pounding and complain about the low PPS makes little sense to me. Edstrom does not appear to me to be CEO material. This was even more apparent at the GS 'interview' with the same analyst who slammed the company just three months ago. He should have sent a note declining the opportunity to explain anything to Olson...his, Olson's, mind was made up already. Mannkind needs a leader, not just someone with tenure. I give the company another six months to pull up their socks and be a partner to Sanofi rather than the mouse in the corner.
|
|
|
Post by orlon on Jun 10, 2015 17:49:20 GMT -5
Interviewed by Jay Olson, the same analyst who issued the sell recommendation a month or so ago. What can possibly go wrong here?
|
|
|
Post by orlon on Jun 10, 2015 17:46:15 GMT -5
Interviewed by the same analyst that issued the sell recommendation a month or two ago. I' m sure this will sell well.
|
|
|
Post by orlon on Jun 10, 2015 14:39:55 GMT -5
But as Lt.Gen Puller once said during the race to the Yalu River during the Korean War and surrounded by ten divisions of Chinese troops: "Poor bastards. They got us right where we want them."
|
|
|
Post by orlon on Jun 10, 2015 14:04:56 GMT -5
It appears the shorts are doing their best to drive the price back down after Monday' nice run up. Just a gut feeling, but I sense a degree of desperation in the past two days of trading. Something has to give, especially with short interest at 131 million shares.
|
|
|
Post by orlon on Jun 10, 2015 13:59:38 GMT -5
Frustrating isn't it.
|
|
|
Post by orlon on May 21, 2015 16:30:32 GMT -5
Sanofi is the marketing partner...their job is to market this product and we should, as shareholders, expect them to do their job. If they won't put their weight behind an outstanding product maybe it's time to look around for another pharma that will. Hakan Edstrom at the moment appears to be a very weak CEO. He needs to stand up and take charge of the company, create a vision, and organize a management team that achieve that vision. The milestone payments seem to be the only goals at the moment. Getting AFREZZA into the hands of those who need it as well as educating endos on the use and benefits should be the priority here. Hakan needs to think long term...no more excuses!
|
|
|
Post by orlon on May 21, 2015 11:14:27 GMT -5
Looks like the appointment of Dr. Shannon had a negative impact on the stock price. I wonder if anyone asked about shareholder value at the ASM.
|
|